Physician profile
Glenda Kaminski
NPI 1073072203
$4,924.86
in general payments reported to CMS, 2019-2025
27 companies · $1,338 in 2025
The $1,338 reported for 2025 was more than what 76% of Oncology (Clinical Nurse Specialist) providers received nationally (typical 2025 total: $263).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $837 · 2022: $504 · 2023: $963 · 2024: $1,282 · 2025: $1,338.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,398 · Education: $185.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,398.28 |
| Education | $184.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $1,651.07 | 2021-2025 | Lynparza, Imfinzi, Enhertu |
| E.R. Squibb & Sons, L.L.C. | $775.38 | 2022-2025 | Reblozyl, Pomalyst, Opdivo |
| Abbvie INC. | $253.79 | 2024-2025 | |
| Astellas Pharma US INC | $223.26 | 2024-2025 | Vyloy |
| Jazz Pharmaceuticals INC. | $216.44 | 2021-2023 | |
| Daiichi Sankyo INC. | $158.34 | 2021-2025 | Datroway |
| Becton, Dickinson and Company | $154.24 | 2025 | Powerpicc |
| Stemline Therapeutics INC. | $134.68 | 2025 | Orserdu |
| Taiho Oncology, INC. | $126.00 | 2024-2025 | |
| Sobi, INC | $125.00 | 2024 | |
| Pfizer INC. | $119.59 | 2025 | |
| Stryker Corporation | $116.69 | 2023 | Sage Self Oral Care |
| Bayer Healthcare Pharmaceuticals INC. | $104.00 | 2021 | |
| Rigel Pharmaceuticals, INC. | $93.93 | 2021 | |
| Caris Mpi, INC. | $83.99 | 2025 | Mi Cancer Seek |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novocure INC. | $78.13 | 2024 | Optune |
| Takeda Pharmaceuticals U.S.A., INC. | $78.00 | 2022 | |
| Puma Biotechnology, INC. | $76.40 | 2021 | |
| Inari Medical, INC. | $63.90 | 2024 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Genzyme Corporation | $58.60 | 2024 | |
| Novartis Pharmaceuticals Corporation | $52.20 | 2025 | |
| Medline Industries Lp | $43.15 | 2023-2024 | |
| Kite Pharma, INC. | $41.72 | 2023 | Yescarta |
| Pharmacosmos Therapeutics INC. | $40.79 | 2022 | |
| Incyte Corporation | $19.47 | 2025 | Jakafi |
| Janssen Biotech, INC. | $18.09 | 2025 | Tecvayli |
| Springworks Therapeutics, INC. | $18.01 | 2025 | Ogsiveo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Glenda Kaminski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.